Search results
Results from the WOW.Com Content Network
(Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...
About 5% to 10% of female breast cancer patients have a BRCA mutation, according to the American Cancer Society. When breast cancer is diagnosed early, the five-year relative survival rate is over ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic ...
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug ...
Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
The individuals being held are all Chinese citizens who marketed cancer drugs in AstraZeneca's oncology division, according to Bloomberg. China detains AstraZeneca staff in data, drug-import ...
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer ...
Breast cancer is the most common cancer diagnosed among women in the United States and the second leading cause of death from cancer among women, according to the American Cancer Society.